Advertisement: The ONE Group
RealVNC mid banner careers
17 July, 2017 - 10:31 By Tony Quested

Tony Jones succeeds Harriet Fear as One Nucleus CEO

Harriet Fear map biopharma

Harriet Fear has stepped down as chief executive of One Nucleus, the Cambridge-based membership organisation for life science companies, to take a new role with MAP BioPharma.

She has transformed One Nucleus into a globally influential power broker in eight and a half years at the helm.

Tony Jones, currently director of business development at One Nucleus, is taking over as chief executive.

Fear has become chief consulting officer for Cambridge-based MAP BioPharma, which provides services that help BioPharma and MedTech clients achieve optimal pricing and market access. Founded in 2012, the family-run business has developed online resources for the UK & Ireland, France, Germany, Italy and Spain and plans to extend development to include other EU countries. 

Outside Europe, Canada is now available and plans are in place to add Japan, Brazil, Turkey, Australia & New Zealand. MAP’s consultancy services supplement MAP online by providing expert product specific, one to one expert strategic advice on a consulting basis throughout the product lifecycle across the EU.

Chief executive Christian Hill said the company had experienced rapid and sustained growth in the last five years and was now ready to ramp even further globally.

Hill said: “Harriet is the perfect fit for us, with her international focus, strong belief in making a positive difference and understanding the needs and interests of our members.

“Having run the largest membership organisation for the life science and healthcare sector in Europe while chief executive of One Nucleus, she is very well placed to support our future.”

Fear, who was awarded the an MBE in the Queen’s Birthday 2016 Honours List, added: “MAP BioPharma’s offer and values are exceptional. The company has a clear and fantastic offer for the sector. In these difficult times, the importance of demonstration of value, timely and professional advice and hands-on support are critical. I especially appreciate that the whole team is deeply committed to its current and future members.

“Having been chief executive of One Nucleus for over 8 years, it was time for me to seek new challenges and I would only move from what I once described as the best job in the world, to a role which will bring me fresh and exciting challenges and opportunities to support our innovative sector.”

Fear formally assumes her role on September 18. Her successor at One Nucleus, Tony Jones, takes the reins on August 18.

Jones said: “I am very pleased to be taking on the CEO role for the next phase of development of One Nucleus at this exciting time when the region’s life science and healthcare sector is performing so strongly.

“Building on the strong foundations laid to date, I look forward to ensuring One Nucleus increases its abilities further to ensure our members gain the best access possible to the key value drivers for their businesses. 

“Catalysing the correct connectivity will render our region the best place in the world to work, start and grow new companies, translate great innovation and invest in the sector, ultimately for the benefit of our most important collective stakeholder group  – patients facing unmet medical need.”

Advertisement: Barclays Eagle Labs

Newsletter Subscription

Stay informed of the latest news and features